Mendeley出力
＜博士論文＞
原発性肺腺癌における PD-L1 タンパク発現の臨床的意義
| 作成者 | |
|---|---|
| 論文調査委員 | |
| 本文言語 | |
| 学位授与年度 | |
| 学位授与大学 | |
| 学位 | |
| 学位種別 | |
| 出版タイプ | |
| アクセス権 | |
| 関連DOI | |
| 概要 | INTRODUCTION: The clinicopathological features of carcinomas expressing programmed death ligand 1 (PD-L1) and their associations with common driver mutations, such as mutations in the EGFR gene, in lu...ng adenocarcinoma are not clearly understood. Here, we examined PD-L1 protein expression in surgically resected primary lung adenocarcinoma and the association of PD-L1 protein expression with clinicopathological features, EGFR mutation status, and patient outcomes. METHODS:The expression of PD-L1 protein in 417 surgically resected primary lung adenocarcinomas was evaluated by immunohistochemical analysis. The cutoff value for defining PD-L1 positivity was determined according to the histogram of proportions of PD-L1-positive cancer cells. RESULTS:Samples from 85 patients (20.4%) and 144 patients (34.5%) were positive for PD-L1 protein expression according to 5% and 1% PD-L1 cutoff values, respectively. Fisher's exact tests showed that PD-L1 positivity was significantly associated with male sex, smoking, higher tumor grade, advanced T status, advanced N status, advanced stage, the presence of pleural and vessel invasions, micropapillary or solid predominant histological subtypes, and wild-type EGFR. Univariate and multivariate survival analyses revealed that patients with PD-L1 positivity had poorer prognoses than those without PD-L1 protein expression at the 1% cutoff value (disease-free survival p < 0.0001, overall survival p < 0.0001). CONCLUSIONS:PD-L1 protein expression was significantly higher in smoking-associated adenocarcinoma and in EGFR mutation-negative adenocarcinoma. PD-L1 protein expression was associated with poor survival in patients with lung adenocarcinoma. The PD-L1/programmed cell death 1 pathway may contribute to the progression of smoking-associated tumors in lung adenocarcinoma.続きを見る |
本文ファイル
| ファイル | ファイルタイプ | サイズ | 閲覧回数 | 説明 |
|---|---|---|---|---|
med2953
|
2.15 MB | 419 | 本文 | |
|
med2953_abstract
|
91.9 KB | 219 | 要旨 | |
|
med2953_summary
|
91.9 KB | 384 | 要約 | |
|
med2953_review
|
175 KB | 280 | 審査結果要旨 |
詳細
| レコードID | |
|---|---|
| 査読有無 | |
| 権利関係 | |
| 関連PubMed ID | |
| 報告番号 | |
| 学位記番号 | |
| 授与日(学位/助成/特許) | |
| 受理日 | |
| 部局 | |
| 登録日 | 2017.05.12 |
| 更新日 | 2020.10.09 |